News & Analysis as of

European Medicines Agency (EMA) Coronavirus/COVID-19

Jones Day

EU Emergency Response Update – Key Policy & Regulatory Developments No. 104

Jones Day on

This regular alert covers key regulatory developments related to EU emergency responses, including in particular, to COVID-19, Russia’s war of aggression on against Ukraine, and cyber threats. It does not purport to provide...more

Jones Day

EU Emergency Response Update – Key Policy & Regulatory Developments No. 103

Jones Day on

This regular alert covers key regulatory developments related to EU emergency responses, including in particular, to COVID-19, Russia’s war of aggression on against Ukraine, and cyber threats. ...more

Jones Day

COVID-19 Key EU Developments, Policy & Regulatory Update No. 86

Jones Day on

This regular alert covers key regulatory EU developments related to the COVID-19 situation. It does not purport to provide an exhaustive overview of developments and contains no analysis or opinion. ...more

Faegre Drinker Biddle & Reath LLP

COVID-19 Weekly Newsletter: Variants and Vaccine Hesitancy

As the delta variant becomes more prominent in the U.S., public health authorities look for ways to address vaccine hesitancy, and the scientific community seeks to better understand viruses — as our list of identified...more

Jones Day

COVID-19 Key EU Developments, Policy & Regulatory Update No. 45

Jones Day on

LATEST KEY DEVELOPMENTS Competition & State Aid • Portugal is first Member State to officially deliver Recovery and Resilience Plan to European Commission • EU Single Resolution Board responds to European...more

Jones Day

COVID-19 Key EU Developments, Policy & Regulatory Update No. 42

Jones Day on

LATEST KEY DEVELOPMENTS - Competition & State Aid • European Commission issues Comfort letter on Cooperation at a Matchmaking Event – Towards COVID19 vaccines upscale production • European Commission publishes...more

Jones Day

COVID-19 Key EU Developments, Policy & Regulatory Update No. 41

Jones Day on

LATEST KEY DEVELOPMENTS - Competition & State Aid • Commissioner McGuinness addresses EU’s bank crisis management and deposit insurance framework, including COVID-19 crisis and State aid concerns • EU approves...more

Jones Day

COVID-19 Key EU Developments, Policy & Regulatory Update No. 39

Jones Day on

LATEST KEY DEVELOPMENTS Competition & State Aid • European Commission pursues Fit for Future Platform to simplify EU law, including in the area of State aid, particularly in response to the pandemic • EU approves new...more

A&O Shearman

Regulatory Considerations For Covid-19 Next Generation Vaccines

A&O Shearman on

As next generation Covid-19 vaccine developers consider whether ethical and practical clinical efficacy trials can be conducted, they might consider whether vaccine efficacy can instead be inferred. We consider the...more

Hogan Lovells

Coronavirus: The Hill and the Headlines, January 2021 # 8

Hogan Lovells on

In Washington: The House voted 232-197 to impeach President Trump for a second time on a charge of inciting insurrection over the Jan. 6 siege on the U.S. Capitol that left five people, including a Capitol Police officer,...more

Jones Day

COVID-19 Key EU Developments, Policy & Regulatory Update No. 28

Jones Day on

LATEST KEY DEVELOPMENTS - Competition & State Aid • EU approves new and amended Member State measures to support the economy • Executive Vice-President and Competition Commissioner Vestager speech on the future of State...more

Hogan Lovells

EMA publishes list of COVID-19 treatments that have been the subject of the Agency’s guidance

Hogan Lovells on

On 30 October 2020, the European Medicines Agency (“EMA”) published a list containing all COVID-19 treatments and vaccines that have so far been the subject of scientific advice or informal guidance from EMA’s pandemic Task...more

Hogan Lovells

COVID-19: Daily Report for Life Sciences and Health Care Companies (UPDATED)

Hogan Lovells on

The Daily Report is a compilation of COVID-19 (coronavirus) news briefs from around the world to help life sciences and health care companies stay current in this challenging time....more

Hogan Lovells

Spain’s AEMPS clarifies position on hydroxychloroquine, echoing statements of EMA and Lancet

Hogan Lovells on

The Spanish Agency for Medicinal Products and Medical Devices (AEMPS) stated that it will not take, for the time being, any regulatory action to temporarily suspend or halt the recruitment of patients for clinical trials to...more

King & Spalding

Accelerated Covid-19 Vaccine Clinical Trials

King & Spalding on

Liability exposure and shields for vaccine developers - As the number of COVID-19 cases continues to rise every day, efforts to develop vaccines across the globe have hit record speeds. In the U.S., the U.S. Food and Drug...more

McDermott Will & Emery

COVID-19, Brexit, and Ongoing EU and UK Regulatory Initiatives for Product Compliance

The year 2020 has brought a host of unique challenges for EU product importers and manufacturers, including those in the chemical sector. Just as most businesses got to grips with their preparation for the disruption caused...more

King & Spalding

Europe Update – Life Sciences Products and COVID-19: From Clinical Trials to Regulatory Flexibility

King & Spalding on

In March, most European Union (‘EU’) countries ordered some form of lockdown and adopted many national measures to address or prevent issues raised by COVID-19. The health crisis pushed national authorities to focus on their...more

Hogan Lovells

EU Guidance to sponsors, investigators on how to manage clinical trials during the COVID-19 pandemic

Hogan Lovells on

In addition to guidance issued by European Union (EU) Member States on the conduct of clinical trials during the COVID-19 pandemic, harmonized EU guidance has now been issued. On Friday, March 20, the European Commission, the...more

18 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide